Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
7.10
+0.23 (3.35%)
Apr 8, 2026, 11:31 AM EDT - Market open
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $339.15 million as of April 8, 2026. Its market cap has increased by 288.09% in one year.
Market Cap
339.15M
Enterprise Value
168.06M
1-Year Change
288.09%
Ranking
Category
Stock Price
$7.10
Market Cap Chart
Since August 10, 2021, Climb Bio's market cap has decreased from $403.20M to $339.15M, a decrease of -15.88%. That is a compound annual growth rate of -3.64%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 7, 2026 | 328.17M | 71.83% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | 403.20M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Rezolute | 342.78M |
| Cabaletta Bio | 341.76M |
| Bicycle Therapeutics | 341.56M |
| X4 Pharmaceuticals | 339.13M |
| Immuneering | 338.13M |
| Ovid Therapeutics | 337.60M |
| Neurogene | 325.66M |
| NervGen Pharma | 321.30M |